Peptide receptor radionuclide therapy for malignant insulinoma: New horizons

Malignant insulinoma is a rare neuroendocrine tumor, located exclusively in the pancreas, characterized by severe hypoglycemia secondary to excessive insulin secretion. Somatostatin analogs (SSA) and everolimus have been added classic treatment with diazoxide last years. Peptide receptor radionuclide therapy (PRRT) has also recently tested few patients apparently satisfactory results. We present 49-year-old woman loss of consciousness context that was diagnosed malignant insulinoma. She underwent tumor excision total pancreatectomy after an extended hospital stay, she discharged without under ASS. After observing progression, 4 cycles PRRT performed symptomatic control, reduction some metastatic lesions stabilization other excellent tolerance treatment. possible alternative for etiological